Mostrar el registro sencillo del ítem
dc.contributor.author
Moreno, María Cecilia
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.contributor.author
Giagante, Brenda
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.contributor.author
Saidon, Patricia Claudia
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.contributor.author
Kochen, Sara Silvia
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.contributor.author
Benozzi, Jorge
dc.contributor.author
Rosenstein, Ruth Estela
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.date.available
2021-12-09T12:20:32Z
dc.date.issued
2014-12
dc.identifier.citation
Moreno, María Cecilia; Giagante, Brenda; Saidon, Patricia Claudia; Kochen, Sara Silvia; Benozzi, Jorge; et al.; Visual defects associated with vigabatrin: a study of epileptic argentine patients; Cambridge University Press; Canadian Journal of Neurological Sciences; 32; 4; 12-2014; 459-464
dc.identifier.issn
0317-1671
dc.identifier.uri
http://hdl.handle.net/11336/148463
dc.description.abstract
Objective: The aim of the present study was to assess visual alterations in a population of Argentine patients treated with the antiepileptic drug vigabatrin. Methods: Twenty patients receiving vigabatrin and 15 patients receiving carbamazepine were examined with automated perimetry using a Humphrey 120-point full screening strategy. In addition, scotopic flash electroretinograms were performed. Results: Of 20 patients treated with vigabatrin, two were unable to cooperate with testing. Of the remaining 18 patients, all but two showed at least one non-detected point inside the central 40° of the visual field of each eye. Of the 15 carbamazepine-treated patients, three were unable to perform the study. None of the remaining 12 patients showed visual field defects. Both a- and b-wave amplitudes of the scotopic electroretinogram were significantly reduced in 12 patients receiving vigabatrin.The aim of the present study was to assess visual alterations in a population of Argentine patients treated with the antiepileptic drug vigabatrin. Methods: Twenty patients receiving vigabatrin and 15 patients receiving carbamazepine were examined with automated perimetry using a Humphrey 120-point full screening strategy. In addition, scotopic flash electroretinograms were performed. Results: Of 20 patients treated with vigabatrin, two were unable to cooperate with testing. Of the remaining 18 patients, all but two showed at least one non-detected point inside the central 40° of the visual field of each eye. Of the 15 carbamazepine-treated patients, three were unable to perform the study. None of the remaining 12 patients showed visual field defects. Both a- and b-wave amplitudes of the scotopic electroretinogram were significantly reduced in 12 patients receiving vigabatrin.Methods: Twenty patients receiving vigabatrin and 15 patients receiving carbamazepine were examined with automated perimetry using a Humphrey 120-point full screening strategy. In addition, scotopic flash electroretinograms were performed. Results: Of 20 patients treated with vigabatrin, two were unable to cooperate with testing. Of the remaining 18 patients, all but two showed at least one non-detected point inside the central 40° of the visual field of each eye. Of the 15 carbamazepine-treated patients, three were unable to perform the study. None of the remaining 12 patients showed visual field defects. Both a- and b-wave amplitudes of the scotopic electroretinogram were significantly reduced in 12 patients receiving vigabatrin.Results: Of 20 patients treated with vigabatrin, two were unable to cooperate with testing. Of the remaining 18 patients, all but two showed at least one non-detected point inside the central 40° of the visual field of each eye. Of the 15 carbamazepine-treated patients, three were unable to perform the study. None of the remaining 12 patients showed visual field defects. Both a- and b-wave amplitudes of the scotopic electroretinogram were significantly reduced in 12 patients receiving vigabatrin. Conclusions: Visual field defects among patients on vigabatrin therapy may occur with a higher frequency than previously recognized. The Humphrey 120-points full field screening test and electroretinography are useful tools to assess the visual dysfunction associated with vigabatrin.Visual field defects among patients on vigabatrin therapy may occur with a higher frequency than previously recognized. The Humphrey 120-points full field screening test and electroretinography are useful tools to assess the visual dysfunction associated with vigabatrin.
dc.description.abstract
Objectif: Le but de cette étude était d’évaluer les changements visuels chez un groupe de patients argentins traités par le vigabatrin, un médicament anti-épileptique. Méthodes: Vingt patients recevant du vigabatrin et 15 patients recevant de la carbamazépine ont subi une périmétrie de dépistage plein écran de 120 points au moyen de l’appareil automatisé Humphrey. De plus, des électrorétinogrammes au flash scotopique ont été effectués. Résultats: L’étude n’a pu être réalisée chez deux des 20 patients traités par le vigabatrin à cause de leur manque de coopération. Chez les 18 autres patients, tous sauf deux avaient au moins un point non détecté au champ visuel central de 40o de chaque œil. Trois des 15 patients recevant de la carbamazépine n’ont pu compléter l’étude. Aucun des 12 autres patients n’avait de déficit au niveau des champs visuels. L’amplitude des ondes a et b de l’électrorétinogramme scotopique était significativement diminuée chez 12 patients recevant le vigabatrin. Conclusions: Des anomalies du champ visuel sont peut-être plus fréquentes qu’on ne l’estimait chez les patients recevant du vigabatrin. La périmétrie automatisée Humphrey plein écran de 120 points et l’électrorétinographie sont des méthodes utiles pour évaluer la dysfonction visuelle associée au vigabatrin.
dc.format
application/pdf
dc.language.iso
eng
dc.publisher
Cambridge University Press
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.rights
info:eu-repo/semantics/openAccess
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.subject.classification
Neurología Clínica
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.subject.classification
Medicina Clínica
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.title
Visual defects associated with vigabatrin: a study of epileptic argentine patients
dc.title
Déficits visuels associés au vigabatrin: étude de patients argentins
dc.type
info:eu-repo/semantics/article
dc.type
info:ar-repo/semantics/artículo
dc.type
info:eu-repo/semantics/publishedVersion
dc.date.updated
2021-07-26T17:12:54Z
dc.identifier.eissn
2057-0155
dc.journal.volume
32
dc.journal.number
4
dc.journal.pagination
459-464
dc.journal.pais
Reino Unido
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.description.fil
Fil: Moreno, María Cecilia. Gobierno de la Ciudad de Buenos Aires. Hospital General de Agudos "Ramos Mejía"; Argentina
dc.description.fil
Fil: Giagante, Brenda. Gobierno de la Ciudad de Buenos Aires. Hospital General de Agudos "Ramos Mejía"; Argentina
dc.description.fil
Fil: Saidon, Patricia Claudia. Gobierno de la Ciudad de Buenos Aires. Hospital General de Agudos "Ramos Mejía"; Argentina
dc.description.fil
Fil: Kochen, Sara Silvia. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Biología Celular y Neurociencia "Prof. Eduardo de Robertis". Universidad de Buenos Aires. Facultad de Medicina. Instituto de Biología Celular y Neurociencia; Argentina
dc.description.fil
Fil: Benozzi, Jorge. Gobierno de la Ciudad de Buenos Aires. Hospital General de Agudos "Ramos Mejía"; Argentina
dc.description.fil
Fil: Rosenstein, Ruth Estela. Gobierno de la Ciudad de Buenos Aires. Hospital General de Agudos "Ramos Mejía"; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
dc.journal.title
Canadian Journal of Neurological Sciences
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://www.cambridge.org/core/journals/canadian-journal-of-neurological-sciences/article/visual-defects-associated-with-vigabatrin-a-study-of-epileptic-argentine-patients/E6FB0A302FF42D7F76B828481FDD2D1C
Archivos asociados